Doxapram
Dopram (doxapram) is a small molecule pharmaceutical. Doxapram was first approved as Dopram on 1982-01-01. It is used to treat hypercapnia, respiratory hypersensitivity, and substance-related disorders in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Dopram (generic drugs available since 2003-01-10)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Doxapram hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DOPRAM | Hikma Pharmaceuticals | N-014879 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dopram | New Drug Application | 2021-02-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypercapnia | — | D006935 | — |
| respiratory hypersensitivity | — | D012130 | — |
| substance-related disorders | EFO_0003890 | D019966 | F13 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
141 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 18 | 16 | 20 | 7 | 8 | 65 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | 2 | 1 | 4 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | — | 3 | — | 4 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | 1 | 1 | 3 |
| Depression | D003863 | F33.9 | — | — | — | 1 | 1 | 2 | |
| Kidney transplantation | D016030 | — | — | — | 1 | 1 | 2 | ||
| Sepsis | D018805 | A41.9 | 1 | — | — | 1 | — | 2 | |
| Prolactinoma | D015175 | HP_0006767 | — | — | — | 1 | 1 | 2 | |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | — | 1 | — | 1 | |
| Anhedonia | D059445 | R45.84 | — | — | — | 1 | — | 1 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypotension | D007022 | EFO_0005251 | I95 | 2 | — | 1 | — | 3 | 6 |
| Cocaine-related disorders | D019970 | F14 | 1 | 1 | 1 | — | — | 2 | |
| Septic shock | D012772 | A48.3 | — | — | 2 | — | — | 2 | |
| Shock | D012769 | R57.1 | — | — | 2 | — | — | 2 | |
| Blood transfusion | D001803 | — | — | 1 | — | 1 | 2 | ||
| Anesthesia | D000758 | — | — | 1 | — | 1 | 2 | ||
| Dyskinesias | D020820 | G24 | — | — | 1 | — | — | 1 | |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | 1 | — | — | 1 |
| Cerebral intraventricular hemorrhage | D000074042 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 5 | — | — | — | 5 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | 2 | 2 | — | — | 1 | 3 |
| Acute pain | D059787 | R52 | — | 2 | — | — | — | 2 | |
| Brain diseases | D001927 | HP_0001298 | G93.40 | 2 | 2 | — | — | — | 2 |
| Nervous system diseases | D009422 | G00-G99 | 2 | 2 | — | — | — | 2 | |
| Movement disorders | D009069 | EFO_0004280 | G25 | 2 | 2 | — | — | — | 2 |
| Chronic pain | D059350 | HP_0012532 | — | 2 | — | — | — | 2 | |
| Retinitis pigmentosa | D012174 | HP_0000580 | H35.52 | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | 1 | — | — | — | — | 1 | |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | — | — | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | 1 | — | — | — | — | 1 |
| Hypoxia | D000860 | R09.02 | 1 | — | — | — | — | 1 | |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | — | — | 1 |
| Blood pressure | D001794 | EFO_0004325 | 1 | — | — | — | — | 1 | |
| Disease progression | D018450 | 1 | — | — | — | — | 1 | ||
| Neurologic gait disorders | D020233 | R26.1 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pure autonomic failure | D054970 | — | — | — | — | 1 | 1 | ||
| Multiple system atrophy | D019578 | — | — | — | — | 1 | 1 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Weight loss | D015431 | HP_0001824 | — | — | — | — | 1 | 1 | |
| Adiposity | D050154 | — | — | — | — | 1 | 1 | ||
| Neonatal sepsis | D000071074 | HP_0040187 | — | — | — | — | 1 | 1 | |
| Renal artery obstruction | D012078 | EFO_1001150 | N28.0 | — | — | — | — | 1 | 1 |
| Dystonic disorders | D020821 | G24 | — | — | — | — | 1 | 1 | |
| Dystonia | D004421 | HP_0001332 | G24 | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DOXAPRAM |
| INN | doxapram |
| Description | Doxapram is a member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering. It has a role as a central nervous system stimulant. It is a member of morpholines and a member of pyrrolidin-2-ones. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 309-29-5 |
| RxCUI | 3637 |
| ChEMBL ID | CHEMBL1754 |
| ChEBI ID | 681848 |
| PubChem CID | 3156 |
| DrugBank | DB00561 |
| UNII ID | 94F3830Q73 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 723 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,129 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more